Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160434 | 0.86 | CA12 (0.65) | CA2CA12CA1CA7CA9 | |
| SCHEMBL3165577 | 0.86 | CA12 (0.65) | CA2CA12CA1CA7CA9 | |
| SCHEMBL7470873 | 0.82 | MAOB (0.52) | ACHEALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL10913701 | 0.82 | MAPT (0.44) | CA2CA12CA1CA7CA9 | |
| SCHEMBL28900582 | 0.81 | CA2 (0.53) | CA2CA12CA1CA7CA9 | |
| SCHEMBL9715643 | 0.81 | CA2 (0.64) | CA2CA12CA1CA7CA9 | |
| SCHEMBL12100424 | 0.79 | CA2 (0.61) | CA2CA12CA1CA7CA9 | |
| SCHEMBL13978302 | 0.79 | CA2 (0.61) | CA2CA12CA1CA7CA9 | |
| SCHEMBL28203223 | 0.79 | CA2 (0.61) | CA2CA12CA1CA7CA9 | |
| SCHEMBL24436737 | 0.79 | ALDH1A1 (0.58) | CA2CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0131509-A2 | Photographic element containing a polymeric mordant comprising quaternized vinylimidazole and acrylonitrile recurring units | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-01-16 | — | — | EP | claimed |
| US-4450224-A | CATIONIC IMIDAZOLE-CONTAINING VINYL POLYMERS FOR SILVER HALIDE COLOR FILMS | EASTMAN KODAK COMPANY (US) | 1984-05-22 | — | — | US | claimed |
| US-9914732-B2 | Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2018-03-13 | — | — | US | disclosed |
| EP-3097103-B1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-11-15 | — | — | EP | disclosed |
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2017-01-05 | — | — | US | disclosed |
| EP-3097103-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015110271-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-07-30 | — | — | WO | disclosed |
| CN-101277931-B | Synthetic method for preparing aminocyclohexyl ether compound | CARDIOME PHARMA CORP | 2013-04-24 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-1994019339-A1 | PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-4943514-A | POLYMERIC MORDANT FROM QUATERNIZED VINYLIMIDAZOLE | EASTMAN KODAK COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4942103-A | POLYVINYL ALCOHOL BINDERS, RADIATION SENSITIVE DICHROMATES, A POLYMERIC MORDANT OF QUATERNIZED N-VINYLIMIDAZOLES | EASTMAN KODAK COMPANY (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0131509-A2 | Photographic element containing a polymeric mordant comprising quaternized vinylimidazole and acrylonitrile recurring units | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-01-16 | — | — | EP | disclosed |
| US-4450224-A | CATIONIC IMIDAZOLE-CONTAINING VINYL POLYMERS FOR SILVER HALIDE COLOR FILMS | EASTMAN KODAK COMPANY (US) | 1984-05-22 | — | — | US | disclosed |
| US-4302588-A | 5-(3-SUBSTITUTED AMINO)-2-HYDROXY-PROPYLOXY)-8-HYDROXY OR ALKOXY-CARBOSTYRILS, ADRENERGIC BLOCKING AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-24 | — | — | US | disclosed |
| US-4289883-A | ADRENERGIC BLOCKING AGENTS OF EXCELLENT CARDIOSELECTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-15 | — | — | US | disclosed |
| US-4210753-A | TREATMENT OF CARDIAC DISORDERS AND CHRONIC LUNG DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | disclosed |
| US-4147869-A | ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | SNCA, DDT, DRD1 | CA2 4834/4885CA12 4374/4885CA1 3658/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | CA2 3688/4885CA12 4570/4885CA1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.